1区 · 医学
Letter
作者: O’Brien, Tracey A. ; McCaughan, Georgia ; Jiang, Wei ; Sutrave, Gaurav ; Moezzi, Leili ; Maddock, Karen ; Street, Janine A. ; Gottlieb, David J. ; Mathew, Geetha ; Clancy, Leighton E. ; Avdic, Selmir ; Bishop, David C. ; Shaw, Peter J. ; Lee, Koon ; Antonenas, Vicki ; Simms, Renee ; Burgess, Jane ; Micklethwaite, Kenneth P. ; McGuire, Helen M. ; Atkins, Elissa ; Blyth, Emily ; Gloss, Brian S. ; Irving, David O.
CD19 -specific chimeric antigen receptor (CAR19) T cells induce remission of B cell malignancy, but manufacture of individualized autologous products with viral vectors is expensive, delays treatment, risks contamination with malignant B cells, and is not feasible in patients with insufficient healthy T cells.Generation of CAR19 T cells using an allogeneic donor is a promising alternative strategy, but limited data exist regarding safety and efficacy.Here, authors demonstrate that allogeneic piggyBac CAR19 T cells administered post-HSCT achieve the efficacy seen with CAR T cells generated using viral vectors.However, recruitment to trials of piggyBac CAR19 T cells at our center has been voluntarily suspended while further investigations into the pathogenesis of CAR19 T-cell lymphoma take place.The ability of piggyBac to integrate a large amount of genetic material, and the absence of a requirement for detection of competent retrovirus or lentivirus in the final product, remain attractive characteristics of this system.
